Leukemia research · 2011
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.
Оценочное исследованиеСтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Latagliata Roberto, Breccia Massimo, Castagnetti Fausto, Stagno Fabio, Luciano Luigiana, Gozzini Antonella, Ulisciani Stefano, Cavazzini Francesco, Annunziata Mario, Sorà Federica, Rossi Antonella Russo, Pregno Patrizia, Montefusco Enrico, Abruzzese Elisabetta, Crisà Elena, Musto Pellegrino, Tiribelli Mario, Binotto Gianni, Occhini Ubaldo, Feo Costanzo, Vigneri Paolo, Santini Valeria, Fava Carmen, Rosti Giannantonio, Alimena Giuliana
Аннотация
To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher in patients with 140 mg starting dose (50.0% vs 19.6%, p=0.001). Grade 3-4 pleuro-pericardial effusions occurred in 10 patients (8.0%). Dose reductions were more common in patients with 140 mg (88.4% vs 26.7%, p<0.001). Of 122 evaluable patients, 72 (59.1%) had cytogenetic response [12 (9.8%) partial, 60 (49.3%) complete]. Overall, 38/60 patients in complete CyR also achieved a molecular response. Cumulative OS at 24 and 48 months were 93.1% (95% CI 88.4-97.8) and 84.2% (95% CI 74.6-93.7). Dasatinib, at the recommended dose of 100mg/day, is effective and safe also in unselected elderly subjects.